{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T19:04:00Z","timestamp":1776452640962,"version":"3.51.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03629-2","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T15:29:38Z","timestamp":1734190178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effective omalizumab dosage for chronic urticaria: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"317","author":[{"given":"Amin","family":"Tajerian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Pourvali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Khoshkhui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehraneh","family":"Movahedi Aliabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahya","family":"Mobinikhaledi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9094-6999","authenticated-orcid":false,"given":"Arezoo","family":"Faridzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,14]]},"reference":[{"issue":"3","key":"3629_CR1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","volume":"77","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T et al (2022) The international EAACI\/GA\u00b2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 77(3):734\u2013766","journal-title":"Allergy"},{"issue":"2","key":"3629_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/all.14037","volume":"75","author":"J Fricke","year":"2020","unstructured":"Fricke J et al (2020) Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy 75(2):423\u2013432","journal-title":"Allergy"},{"issue":"6","key":"3629_CR3","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/bjd.14768","volume":"175","author":"S Guillen-Aguinaga","year":"2016","unstructured":"Guillen-Aguinaga S et al (2016) Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta\u2010analysis. Br J Dermatol 175(6):1153\u20131165","journal-title":"Br J Dermatol"},{"key":"3629_CR4","unstructured":"Augustin M et al Characteristics and Outcomes of Patients Treated With Apremilast in the Real World: Results From the APPRECIATE Study Target Journal: JEADV Word count: 3080 Tables: 4 (+\u20091 supplementary)."},{"issue":"2","key":"3629_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1365-2133.2005.06385.x","volume":"152","author":"J Grob","year":"2005","unstructured":"Grob J et al (2005) Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 152(2):289\u2013295","journal-title":"Br J Dermatol"},{"issue":"7","key":"3629_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1034\/j.1398-9995.2003.00091.x","volume":"58","author":"I Baiardini","year":"2003","unstructured":"Baiardini I et al (2003) Quality of life and patients\u2019 satisfaction in chronic urticaria and respiratory allergy. Allergy 58(7):621\u2013623","journal-title":"Allergy"},{"issue":"2","key":"3629_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x","volume":"136","author":"B O\u2019donnell","year":"1997","unstructured":"O\u2019donnell B et al (1997) The impact of chronic urticaria on the quality of life. Br J Dermatol 136(2):197\u2013201","journal-title":"Br J Dermatol"},{"issue":"8","key":"3629_CR8","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/1346-8138.14502","volume":"45","author":"A Itakura","year":"2018","unstructured":"Itakura A et al (2018) Impact of chronic urticaria on quality of life and work in Japan: results of a real-world study. J Dermatol 45(8):963\u2013970","journal-title":"J Dermatol"},{"issue":"4","key":"3629_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.5114\/ada.2018.77666","volume":"35","author":"A Lesiak","year":"2018","unstructured":"Lesiak A et al (2018) Omalizumab for urticaria treatment in clinical practice: a case series. Postepy Dermatol Alergol 35(4):372\u2013374","journal-title":"Postepy Dermatol Alergol"},{"issue":"7","key":"3629_CR10","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/all.12313","volume":"69","author":"T Zuberbier","year":"2014","unstructured":"Zuberbier T et al (2014) The EAACI\/GA(2) LEN\/EDF\/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 69(7):868\u2013887","journal-title":"Allergy"},{"issue":"11","key":"3629_CR11","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1111\/ced.15316","volume":"47","author":"S Denman","year":"2022","unstructured":"Denman S et al (2022) Cost-effectiveness of personalized omalizumab dosing for chronic spontaneous urticaria. Clin Exp Dermatol 47(11):2002\u20132005","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"3629_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2500\/aap.2018.39.4132","volume":"39","author":"J Eghrari-Sabet","year":"2018","unstructured":"Eghrari-Sabet J et al (2018) Real-world use of omalizumab in patients with chronic idiopathic\/spontaneous urticaria in the United States. Allergy Asthma Proc 39(3):191\u2013200","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"3629_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s12890-023-02737-5","volume":"23","author":"M Fathi","year":"2023","unstructured":"Fathi M et al (2023) Evaluating the affordability of asthma, chronic obstructive pulmonary disease, and cystic fibrosis medicines in a middle-income country. BMC Pulm Med 23(1):429","journal-title":"BMC Pulm Med"},{"key":"3629_CR14","unstructured":"Ottawa, Treatment of Adults and Adolescents (12 Years of Age and above) with Chronic Idiopathic Urticaria in Omalizumab (Xolair). 2015: Canadian Agency for Drugs and Technologies in Health. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK362661\/"},{"key":"3629_CR15","unstructured":"GDP per capita (current US$) - Iran, Islamic Rep. (2024) [cited 2024 16-03-2024]; https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD?locations=IR"},{"issue":"11","key":"3629_CR16","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1007\/s13555-023-01040-9","volume":"13","author":"TB Casale","year":"2023","unstructured":"Casale TB et al (2023) Omalizumab for patients with chronic spontaneous urticaria: a narrative review of current status. Dermatol Ther (Heidelb) 13(11):2573\u20132588","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"3629_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","volume":"128","author":"M Maurer","year":"2011","unstructured":"Maurer M et al (2011) Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 128(1):202\u2013209e5","journal-title":"J Allergy Clin Immunol"},{"key":"3629_CR18","doi-asserted-by":"crossref","unstructured":"Saini S et al (2011) A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol, 128(3): p. 567\u2013\u200973.e1.","DOI":"10.1016\/j.jaci.2011.06.010"},{"issue":"1","key":"3629_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","volume":"132","author":"A Kaplan","year":"2013","unstructured":"Kaplan A et al (2013) Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 132(1):101\u2013109","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"3629_CR20","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer M et al (2013) Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 368(10):924\u2013935","journal-title":"N Engl J Med"},{"issue":"1","key":"3629_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/jid.2014.306","volume":"135","author":"SS Saini","year":"2015","unstructured":"Saini SS et al (2015) Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 135(1):67\u201375","journal-title":"J Invest Dermatol"},{"issue":"8","key":"3629_CR22","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/all.12870","volume":"71","author":"P Staubach","year":"2016","unstructured":"Staubach P et al (2016) Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy 71(8):1135\u20131144","journal-title":"Allergy"},{"issue":"3","key":"3629_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/all.13339","volume":"73","author":"P Staubach","year":"2018","unstructured":"Staubach P et al (2018) Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data. Allergy 73(3):576\u2013584","journal-title":"Allergy"},{"issue":"1","key":"3629_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jdermsci.2017.03.009","volume":"87","author":"M Hide","year":"2017","unstructured":"Hide M et al (2017) Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria. J Dermatol Sci 87(1):70\u201378","journal-title":"J Dermatol Sci"},{"issue":"1","key":"3629_CR25","doi-asserted-by":"publisher","first-page":"8985","DOI":"10.1038\/s41598-017-09361-4","volume":"7","author":"E Serrano-Candelas","year":"2017","unstructured":"Serrano-Candelas E et al (2017) Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells. Sci Rep 7(1):8985","journal-title":"Sci Rep"},{"issue":"2","key":"3629_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/cea.13066","volume":"48","author":"L J\u00f6rg","year":"2018","unstructured":"J\u00f6rg L et al (2018) Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients. Clin Exp Allergy 48(2):196\u2013204","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"3629_CR27","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.7150\/thno.18304","volume":"7","author":"M Metz","year":"2017","unstructured":"Metz M et al (2017) Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of Fc\u03b5RI-positive cells in the skin. Theranostics 7(5):1266\u20131276","journal-title":"Theranostics"},{"issue":"4","key":"3629_CR28","doi-asserted-by":"publisher","first-page":"e15303","DOI":"10.1111\/dth.15303","volume":"35","author":"W Yuan","year":"2022","unstructured":"Yuan W et al (2022) Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria. Dermatol Ther 35(4):e15303","journal-title":"Dermatol Ther"},{"issue":"2","key":"3629_CR29","doi-asserted-by":"publisher","first-page":"AB27","DOI":"10.1016\/j.jaci.2020.12.137","volume":"147","author":"R Simpson","year":"2021","unstructured":"Simpson R, Quidwai A, Lee J (2021) Up-dosing to 600\u00a0mg omalizumab for chronic spontaneous urticaria: is it more effective than 300\u00a0mg? J Allergy Clin Immunol 147(2):AB27","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3629_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.anai.2011.09.008","volume":"108","author":"SD Mathias","year":"2012","unstructured":"Mathias SD et al (2012) Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 108(1):20\u201324","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"3629_CR31","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s13555-023-00955-7","volume":"13","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Soong W, Bernstein JA (2023) Chronic spontaneous urticaria: how to measure it and the need to define treatment success. Dermatol Ther (Heidelb) 13(8):1629\u20131646","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"3629_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jdermsci.2013.08.011","volume":"73","author":"M Metz","year":"2014","unstructured":"Metz M et al (2014) Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci 73(1):57\u201362","journal-title":"J Dermatol Sci"},{"key":"3629_CR33","doi-asserted-by":"publisher","unstructured":"Pedersen NH et al (2023) Biomarkers for Monitoring Treatment Response of Omalizumab in patients with chronic Urticaria. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms241411328","DOI":"10.3390\/ijms241411328"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03629-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03629-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03629-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T16:01:57Z","timestamp":1734192117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03629-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,14]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3629"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03629-2","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,14]]},"assertion":[{"value":"10 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}